Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa ST175 in a Hollow-Fiber Infection Model.
P2860
Q26771848-FBE447BB-E6CD-4E3F-A54D-B7BD1C975D14Q36730017-D381D2CE-8EA7-4287-961A-D5BAC450F06CQ36740013-5B665432-1B8E-4DEB-9A59-A9AB1431FE36Q38296151-42B0280C-C054-44B3-85A7-34C555D4A278Q38648594-00C420A6-8D6A-48E5-B1D7-7CEBF6674290Q38690748-F636FCC7-0AED-4568-84AD-30009929F3E3Q38891891-82779A3E-8724-4C65-9EF7-16E7A88105AEQ39704722-384B88B2-837F-49C6-8F73-7CDDFF83FB1EQ40657200-BB0D3B81-F468-4761-88EB-825EE8DC7D94Q41990882-2037C8CF-2A84-48A6-B4A3-723A3AED0C58Q50221890-B9BA72D8-7298-4F76-BC3D-3EC487BCE404Q51741113-91EAAC45-B6A6-4466-A50F-2E6C7F6C8C97
P2860
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Relationship between ceftoloza ...... a hollow-fiber infection model
@ast
Relationship between ceftoloza ...... a hollow-fiber infection model
@en
Relationship between ceftoloza ...... a hollow-fiber infection model
@nl
type
label
Relationship between ceftoloza ...... a hollow-fiber infection model
@ast
Relationship between ceftoloza ...... a hollow-fiber infection model
@en
Relationship between ceftoloza ...... a hollow-fiber infection model
@nl
prefLabel
Relationship between ceftoloza ...... a hollow-fiber infection model
@ast
Relationship between ceftoloza ...... a hollow-fiber infection model
@en
Relationship between ceftoloza ...... a hollow-fiber infection model
@nl
P2093
P2860
P356
P1476
Relationship between ceftoloza ...... a hollow-fiber infection model
@en
P2093
Brian D VanScoy
Jennifer McCauley
Judith N Steenbergen
Lawrence V Friedrich
Paul G Ambrose
Rodrigo E Mendes
Ronald N Jones
Sujata M Bhavnani
P2860
P304
P356
10.1128/AAC.02310-13
P407
P577
2014-07-28T00:00:00Z